The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, particularly in the U.S.

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday, ending a four-year stretch of steady guidance increases since the launch of its Wegovy weight-loss drug,

First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up